IN2012DN00551A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00551A
IN2012DN00551A IN551DEN2012A IN2012DN00551A IN 2012DN00551 A IN2012DN00551 A IN 2012DN00551A IN 551DEN2012 A IN551DEN2012 A IN 551DEN2012A IN 2012DN00551 A IN2012DN00551 A IN 2012DN00551A
Authority
IN
India
Prior art keywords
radioimmunoconjugate
relates
methods
radioimmvmoconjugate
hum195
Prior art date
Application number
Other languages
English (en)
Inventor
Simon Jaime
Gaylord King A
Manuel Moreno Bermudez Josue
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of IN2012DN00551A publication Critical patent/IN2012DN00551A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN551DEN2012 2009-07-22 2010-07-22 IN2012DN00551A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22771009P 2009-07-22 2009-07-22
PCT/US2010/042885 WO2011011592A1 (en) 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates

Publications (1)

Publication Number Publication Date
IN2012DN00551A true IN2012DN00551A (enExample) 2015-06-12

Family

ID=43499411

Family Applications (1)

Application Number Title Priority Date Filing Date
IN551DEN2012 IN2012DN00551A (enExample) 2009-07-22 2010-07-22

Country Status (8)

Country Link
US (1) US9603954B2 (enExample)
EP (1) EP2456472B1 (enExample)
JP (2) JP5985392B2 (enExample)
CN (2) CN104710504B (enExample)
CA (1) CA2768658C (enExample)
IN (1) IN2012DN00551A (enExample)
RU (2) RU2565402C2 (enExample)
WO (1) WO2011011592A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
CN114814055B (zh) * 2015-09-08 2025-03-18 沃特世科技公司 用于分析抗体-药物缀合物的多维色谱方法
CN110290816B (zh) * 2016-12-16 2022-09-30 澳大利亚国立大学 用于靶向施用的放射性标记材料
SI3568205T1 (sl) 2017-01-12 2023-12-29 Radiomedix Inc. Zdravljenje rakastih celic, ki prekomerno izražajo receptorje za somatostatin, z uporabo derivatov okreotida, kelatiranih v radioizotope
ES3049118T3 (en) * 2017-07-31 2025-12-15 Actinium Pharmaceuticals Inc Treatments for a hematological malignancy
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
WO2022056354A1 (en) * 2020-09-11 2022-03-17 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
US12447218B1 (en) * 2021-02-09 2025-10-21 Actinium Pharmaceuticals, Inc. Radioconjugates directed to MHC-complexed antigens in cancer
CN119256014A (zh) 2022-03-24 2025-01-03 锕医药有限责任公司 人源化抗cd45抗体
JPWO2023190402A1 (enExample) 2022-03-30 2023-10-05
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES
WO2025213061A2 (en) 2024-04-04 2025-10-09 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5306509A (en) 1987-03-17 1994-04-26 Turner Robert E Prevention and treatment of oral lesions
IL87405A0 (en) 1987-08-12 1989-01-31 Immunomedics Inc Radiolabeled agents and methods and kits for the production thereof
US4833329A (en) 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
AU630362B2 (en) 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5292868A (en) 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
WO1990015625A1 (en) 1989-06-19 1990-12-27 Akzo N.V. RADIOIMMUNOTHERAPY USING α-PARTICLES EMISSION
WO1991000846A1 (en) 1989-07-12 1991-01-24 Mallinckrodt Medical, Inc. Method for preparing radiodiagnostic gaseous radionuclide and apparatus
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
LU87684A1 (de) 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
WO1999059633A1 (en) 1998-05-20 1999-11-25 Immunomedics, Inc. Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
DE69937797D1 (de) 1998-05-26 2008-01-31 Sloan Kettering Inst Cancer Alpha-emittierende konstrukte sowie deren verwendung
EP1089766B1 (en) 1998-06-22 2010-03-17 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
AU2002211232B2 (en) 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
WO2002080987A1 (en) 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Anti-cd19 immunotoxins
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
CN1612895B (zh) 2002-01-03 2010-05-12 舍林股份公司 包含纤连蛋白ed-b结构域的特异抗体的缀合物和其在检测和治疗肿瘤中的应用
US20040022726A1 (en) * 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060058218A1 (en) * 2004-09-10 2006-03-16 General Electric Company Solid phase conjugation of complexing agents and targeting moieties
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody

Also Published As

Publication number Publication date
CN102596258A (zh) 2012-07-18
RU2015137512A (ru) 2018-12-25
EP2456472B1 (en) 2024-03-27
RU2012106301A (ru) 2013-08-27
JP5985392B2 (ja) 2016-09-06
JP2016199583A (ja) 2016-12-01
CN102596258B (zh) 2015-01-28
EP2456472C0 (en) 2024-03-27
RU2704802C2 (ru) 2019-10-31
JP2013500258A (ja) 2013-01-07
RU2015137512A3 (enExample) 2019-04-02
WO2011011592A1 (en) 2011-01-27
EP2456472A4 (en) 2014-08-27
CN104710504A (zh) 2015-06-17
CA2768658C (en) 2018-04-03
RU2565402C2 (ru) 2015-10-20
US9603954B2 (en) 2017-03-28
CN104710504B (zh) 2019-09-13
HK1211304A1 (en) 2016-05-20
EP2456472A1 (en) 2012-05-30
CA2768658A1 (en) 2011-01-27
US20120220754A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
IN2012DN00551A (enExample)
UA101487C2 (en) Humanized b-ly1 antibody formulation
NZ621170A (en) Anti-human cd52 immunoglobulins
MX2011003855A (es) Metodos para producir anticuerpos a partir de celulas plasmaticas.
IL206639A0 (en) Humanized anti-human nkg2a monoclonal antibody
SG178886A1 (en) Humanized anti-cdcp1 antibodies
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
IL245274B (en) Monoclonal antibodies against the 2her epitope
IL202232A (en) A method of making a human antibody derived from a rabbit parent antibody that binds to a desired antigen as well as a human antibody or fragment thereof produced by this method
EP4477668A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
HUE037095T2 (hu) Eljárások és reagensek monoklonális ellenanyagok elõállítására
GB201108236D0 (en) Method
EP2331579A4 (en) MONOCLONAL ANTIBODIES
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
AP2012006262A0 (en) Monoclonal antibodies to progastrin and their uses.
MX360772B (es) Anticuerpos cd47 y metodos de uso de los mismos.
SG10201601279SA (en) Monoclonal Antibody STRO-4
DK3059337T3 (da) Adaptive immunity profiling og metoder til frembringelse af monoklonale antibodier
IL217000A0 (en) Readily isolated bispecific antibodies with native immunoglobulin format
IL193871A0 (en) Humanized anti-cd20 monoclonal antibody
NZ616382A (en) Antibodies specific to cadherin-17
AP2010005332A0 (en) Humanized antibodies specific for von willebrand factor.
MY182178A (en) Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
EP1940864A4 (en) PROCESS FOR GENERATING MONOCLONAL ANTIBODIES WITH A VIVO REGION